Navigation Links
Vacuum device increase breasts

Scientists from Georgia have found that, although a vacuum device promoted as a breast-enhancer does increase a woman's cup size, few women may have the time and commitment to use the product. The device, known as the BRAVA system, requires women to wear two plastic domes over their breasts for 10 hours a day for 10 weeks straight.// The domes are connected to a battery operated, computerized vacuum device. Skipping even a day adds a week to the treatment.

However, the device does seem to be a viable alternative to surgery for women who want bigger breasts, according to Dr. Richard J. Greco, of the Georgia Institute for Plastic Surgery in Savannah. It is only appropriate for women who are a B cup or smaller and are willing to commit to the price and time required, he said.

Previous studies conducted by the inventors of BRAVA suggested that the device could lead to tissue growth not just temporary swelling resulting in long-term breast enhancement. Greco, a member of the American Society of Plastic Surgeons' Device and Technology Committee, attempted to verify those results in an independent study.

While many women expressed interest in the device, only eight women ended up in the study.Some women couldn't commit to the time involved, others had breasts that were too large or chests that were too narrow. Some felt the system was not worth the relatively small gain (one cup size) made in breast size.

According to Greco, a few patients dropped out because we could not make a definite statement as to whether or not this tissue growth stimulation would increase their likelihood of breast cancer in the future. The report says, of the original eight, two dropped out "because of the inconvenience the device created in their lives. Three of the six women who completed the study experienced an increase in breast size that was equal to one bra cup or more. The remaining three women experienced roughly half as much breast tissue growth, study findings indicate.

The "amount of enhancement is relative to (the woman's) size," Greco said. However, the increased breast size remains evident up to 15 months later, according to previous reports. Greco's study did not include long-term follow-up data.

The device is "relatively inconvenient, is heavy, and induces a fair amount of skin irritation along the silicone border/skin interface," Greco writes. "Yet the motivation to have larger breasts seems to overcome this in the correctly chosen individual." The system is also known to cause initial swelling that goes down as the treatment continues, Greco said.

And many of the women experienced technical difficulties with malfunctioning equipment and needed 15 to 30 minutes on a biweekly basis with customer service to help them through the process. The system can be worn during sleep but an alarm will sound if the user inadvertently rolls over the cord, Greco said. This can result in sleep deprivation, a reason one woman cited when she dropped out of the study. The other woman dropped out because of the time commitment required, the researcher said.

Although reviewed by the US Food and Drug Administration (FDA), BRAVA is not regulated by the agency. The ideal candidate for BRAVA would be an individual who does not have a full time job, or someone who begins to use the device immediately after work and is able to sleep in it, Greco said.

Those who obtain the roughly $2,000 device from an authorized physician and are not satisfied with the results or with the inconvenience, however, will not be able to obtain a refund, according to the researcher. "Understand that you're trading off the risks of surgery with the inconvenience of having to wear" the BRAVA device, Greco said.


'"/>




Related medicine news :

1. DVT Treatment Vacuums Away Blood Clots – Prevents Disabilit
2. Alerts for safety of heart device
3. FDA approves new device to treat womens bleeding disorder
4. A new hearing device improves hearing
5. New device for detecting artery blockages
6. New device for discerning Osteoarthritis
7. Screening device for ovarian cancer
8. Innovative device aids in advanced heart failure
9. Latest device for identifying Melanomas
10. Useful device makes spinal surgery safer
11. New device aids esophagal cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings to include fashion, ... hottest Korean cosmetics and fashion trends sweeping the nation. The decision to expand beyond ... the great offerings that allow Koreans everywhere to look their best every single day. ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a ... teach and share with the others. “Grandpa's Visit” is the creation of published author, ... that she is much like the character in her book. She shares, “Mr. Rice ...
(Date:9/25/2017)... CA (PRWEB) , ... September 25, 2017 , ... Azadian ... a full-time office in downtown Los Angeles, to service existing clients in the Western ... areas. , “We are seeing an ever-increasing amount of business demand west of the ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our Creative World: ... life and seeks answers in both Eastern and Western religious traditions and spirituality such ... in the mind of humankind for the past thousands of years and still are,” ...
(Date:9/24/2017)... Turks & Caicos Islands, BWI (PRWEB) , ... September 24, 2017 ... ... Islands, the #1 rated resort on TripAdvisor and one of Provo's premier boutique resorts, ... no reported structural damage to the resort after devastating Hurricanes Irma and more recently ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
Breaking Medicine Technology: